Advertisement

Reem Karmali, MD, MS

Articles

Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCL

June 24th 2020

Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.

Dr. Karmali on Treating Older Patients With MCL in the Rituximab Era

June 16th 2020

Reem Karmali, MD, MS, discusses an analysis examining clinical outcomes and predictors of survival in older patients with mantle cell lymphoma in the era of rituximab.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Karmali on Limitations of Intensive Therapy in Older/Medically Unfit Patients With MCL

June 6th 2020

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

Dr. Karmali on Next Steps of Research Regarding Ibrutinib Maintenance in MCL

July 12th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the next steps for research regarding the use of ibrutinib (Imbruvica) as maintenance therapy in mantle cell lymphoma (MCL).

Dr. Karmali on Challenges in MCL

July 11th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses challenges in the field of mantle cell lymphoma (MCL).

Dr. Karmali on the Toxicity Profile of Ibrutinib Maintenance in MCL

July 4th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the toxicity profile of ibrutinib (Imbruvica) maintenance therapy after induction therapy in patients with mantle cell lymphoma (MCL).

Dr. Karmali on Novel Agents in Relapsed/Refractory MCL

June 14th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the use of novel agents in patients with relapsed/refractory mantle cell lymphoma (MCL).

Dr. Karmali on Ibrutinib Maintenance Following Induction in Untreated MCL

June 12th 2019

Reem Karmali, MD, MS, assistant professor of medicine, Northwestern University Feinberg School of Medicine, discusses the preliminary results of a study which examined ibrutinib (Imbruvica) maintenance following induction in treatment-naïve patients with mantle cell lymphoma (MCL).

Advertisement
Advertisement